Skip to main content

Table 4 Univariate and multivariate Cox regression analysis of overall survival

From: Proteomic profiling of breast cancer metabolism identifies SHMT2 and ASCT2 as prognostic factors

Characteristics Univariate analysis SHMT2 ASCT2
   Multivariate analysis Multivariate analysis
  P value Hazard ratio (95% CI) P value Hazard ratio (95% CI) P value
Protein expression high vs. low   1.53 (1.10–2.12) 0.011 1.23 (0.90–1.68) 0.194
Age at surgery (years) <0.001 1.06 (1.03–1.09) <0.001 1.06 (1.03–1.08) <0.001
Tumor size <0.001 Not included   Not included  
  < 2 cm      
 ≥2–-5 cm     
 >5 cm     
Histology 0.306 Not included   Not included  
 Ductal vs. non-ductal      
T stage <0.001     
 T1 vs. ≥T2   1.46 (0.88–2.40) 0.141 1.49 (0.90–2.47) 0.123
Grade <0.001     
 I   Reference   Reference  
 II   1.69 (0.52–5.49) 0.385 1.77 (0.54–5.76) 0.345
 III   2.40 (0.70–8.23) 0.163 2.95 (0.87–9.99) 0.081
Nodal status <0.001     
 N0 vs. ≥N1   1.86 (1.18–2.92) 0.007 1.85 (1.17–2.92) 0.008
Menopausal status 0.001     
 Pre/peri vs. postmenopausal   0.72 (0.28–1.85) 0.489 0.80 (0.31–2.05) 0.64
Receptor status
 ER- vs. ER+ <0.001 Not included   Not included  
 PgR- vs. PgR+ <0.001 Not included   Not included
 HER2- vs. HER2+ 0.682 Not included   Not included
 HR- vs. HR+ <0.001 0.72 (0.42–1.22) 0.217 0.63 (0.37–1.06) 0.082
Receptor-defined subtypes <0.001 Not included   Not included  
 Luminal A-like      
 Luminal B-like (HER2 positive)     
 Luminal B-like (HER2 negative)     
 HER2 positive (non-luminal-like)     
 TNBC     
  1. SHMT2 serine hydroxymethyltransferase 2, ASCT2 ASC amino-acid transporter 2, CI confidence interval, Pre-peri premenopausal/perimenopausal, ER estrogen receptor, PgR progesterone receptor, HER2 human epidermal growth factor receptor 2, TNBC triple negative breast cancer
  2. A p value <0.05 was considered statistically significant